The U.S. Food and Drug Administration today announced that it is updating the warning labels required on three gadolinium-based MRI contrast agents sold in the U.S. due to the risk of nephrogenic systemic fibrosis.
FDA updates warning labels on gadolinium contrast
Sep 8, 2010
Latest in MRI
Gadolinium in ... beer?
August 22, 2025